

Gibson Dunn Expands Drug Pricing and Market Access Capabilities With Preeminent Health Regulatory Lawyer Margaux Hall

Firm News | June 18, 2026

Gibson Dunn announced today that Margaux J. Hall has joined the firm as a partner in its FDA and Health Care and Life Sciences Practice Groups in Washington, D.C. Margaux is a leading health regulatory lawyer who advises pharmaceutical manufacturers, investors, and other entities in the supply chain on drug pricing, market access, and value-based arrangements.

“Margaux is a go-to advisor to clients across the pharmaceutical supply chain on drug pricing and market access issues, and her arrival further strengthens our premier FDA and health care platform,” said Jonathan M. Phillips, Co-Chair of the FDA and Health Care Practice Group. “As pricing and reimbursement issues increasingly influence transactions, commercialization strategy, and investment decisions across the life sciences industry, her specialized expertise—combined with our deep bench across regulatory, transactional, white collar, and litigation disciplines—positions us to advise clients on their most consequential matters.”

“The regulatory and enforcement landscape surrounding drug pricing has become more aggressive, with federal and state authorities increasing their scrutiny of industry,” said Gus Eyer, Co-Chair of the FDA and Health Care and Consumer Protection Practice Groups. “Margaux has been at the forefront of these developments, and her experience enhances our ability to help pharmaceutical and biotech clients manage high-stakes investigations, enforcement actions, and related litigation.”

“Gibson Dunn’s unmatched platform across regulatory, litigation, investigations, and transactional practices creates an exceptionally strong foundation for advising clients on today’s pricing and market access challenges,” said Margaux. “I’m excited to join a team with the breadth, sophistication, and collaborative culture to help life sciences clients navigate one of the industry’s most dynamic and rapidly evolving areas.”

Gibson Dunn’s market-leading FDA and Health Care Practice Group provides clients with strategic advice on complex legal issues related to regulated products and health care services. With a team of more than 80 lawyers spanning 12 offices around the world, the group includes a deep bench of former prosecutors and government officials, including a former Director of the U.S. Department of Justice’s Consumer Protection Branch and a former Deputy General Counsel at the U.S. Department of Health and Human Services.

About Margaux J. Hall

Margaux represents pharmaceutical manufacturers, investors, and others in the supply chain on drug pricing, market access, and value-based arrangements. She advises clients on the transformative legal and policy changes affecting pricing, reimbursement, coverage,

Related People

[Margaux Hall](#)

GIBSON DUNN

and access to drugs, vaccines, and devices. She regularly provides health regulatory counsel on mergers and other transactions, as well as government enforcement and litigation matters.

Margaux has dedicated her career to understanding health care in the U.S. and worldwide; she has pursued a Fulbright Program fellowship to research health care law and health system reform in South Africa and led similar research programs at the World Bank Group. Prior to joining Gibson Dunn, Margaux was a partner at an international law firm.

Related Capabilities

[FDA and Health Care](#)

[Life Sciences](#)